Curesponse

Curesponse’s technology represents the next step in personalized cancer medicine, advancing prediction capabilities beyond genomics to understand how cancer treatments will affect the patient’s tumor cells when they are in their native tumor. The company developed cResponse, a test combined Genomic-Functional assay. The test starts with genomic profiling of the tumor to prioritize potential therapies. Then, together with additional therapies that were recommended by the patient’s oncologist, a short list of drugs and drug combinations is generated and functionally tested on the patient’s tumor. The cResponse functional test preserves the original tumor composition (commonly referred to as the Tumor MicroEnvironment – TME) and its 3D structure to assess the effectiveness of all selected treatments on the tumor cells. This enables cResponse to empirically analyze the effectiveness of the recommended treatments following rapid genomic profiling with very high accuracy.

Curesponse has raised $14M in total funding across 2 rounds. The company is currently at the A stage. Key investors include Undisclosed Investor(s), aMoon Fund, NCL Technology Ventures.

Curesponse was founded in 2017 by Guy Neev (Co-founder & CEO), Seth Salpeter (Co-founder & CTO).

Curesponse operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Test Diagnostics & Screening, with core technologies in Biologicals, Genes. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Curesponse is based in Rehovot, Israel, Center District. The company also has offices abroad.